Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$247M |
| 2 |
Johnson & Johnson
JNJ
|
+$225M |
| 3 |
MON
Monsanto Co
MON
|
+$213M |
| 4 |
AET
Aetna Inc
AET
|
+$208M |
| 5 |
Broadcom
AVGO
|
+$176M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$227M |
| 2 |
Microsoft
MSFT
|
+$224M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$205M |
| 4 |
Nike
NKE
|
+$187M |
| 5 |
Pfizer
PFE
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.75% |
| 2 | Technology | 13.74% |
| 3 | Healthcare | 12.69% |
| 4 | Industrials | 11.51% |
| 5 | Consumer Discretionary | 8.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1701
Douglas Emmett
DEI
$1.96B
| $4.75M | 0.01% |
129,900
-21,900
| -14% | -$792K |
|
1702
Aclaris Therapeutics
ACRS
$851M
| $4.74M | 0.01% |
+174,600
| New | +$4.45M |
|
|
RAVN
1703
DELISTED
Raven Industries Inc
RAVN
| $4.72M | 0.01% |
187,500
-13,000
| -6% | -$309K |
|
1704
Hawkins
HWKN
$2.74B
| $4.72M | 0.01% |
175,000
-73,200
| -29% | -$1.69M |
|
|
ZEUS
1705
DELISTED
Olympic Steel
ZEUS
| $4.71M | 0.01% |
194,500
+34,600
| +22% | +$817K |
|
|
SMC
1706
Summit Midstream
SMC
$482M
| $4.71M | 0.01% |
12,488
+7,741
| +163% | +$2.64M |
|
1707
Silicon Motion
SIMO
$9.12B
| $4.71M | 0.01% |
110,879
+7,905
| +8% | +$361K |
|
1708
Woodward
WWD
$21.9B
| $4.71M | 0.01% |
+68,184
| New | +$4.41M |
|
1709
Climb Global Solutions
CLMB
$532M
| $4.7M | 0.01% |
1,006,000
+82,400
| +9% | +$363K |
|
1710
GSI Technology
GSIT
$270M
| $4.7M | 0.01% |
757,707
+130,207
| +21% | +$702K |
|
|
ACH
1711
DELISTED
Alum Corp of China Ltd
ACH
| $4.7M | 0.01% |
460,100
+101,600
| +28% | +$1.04M |
|
|
CVSA
1712
Covista Inc
CVSA
$4.49B
| $4.69M | 0.01% |
150,300
+33,000
| +28% | +$893K |
|
1713
Townsquare Media
TSQ
$104M
| $4.69M | 0.01% |
450,200
+384,200
| +582% | +$3.55M |
|
1714
Monolithic Power Systems
MPWR
$68.9B
| $4.68M | 0.01% |
57,100
-114,200
| -67% | -$9.17M |
|
1715
New Jersey Resources
NJR
$5.64B
| $4.67M | 0.01% |
131,500
+117,000
| +807% | +$3.97M |
|
|
FLY
1716
DELISTED
Fly Leasing Limited
FLY
| $4.66M | 0.01% |
350,084
+225,884
| +182% | +$2.93M |
|
1717
Chegg
CHGG
$87.5M
| $4.64M | 0.01% |
629,400
-301,452
| -32% | -$2.24M |
|
1718
Simulations Plus
SLP
$371M
| $4.64M | 0.01% |
481,300
-24,700
| -5% | -$224K |
|
|
OPLN
1719
Openlane
OPLN
$4.36B
| $4.64M | 0.01% |
287,450
-1,261,026
| -81% | -$20.1M |
|
|
MOFG
1720
DELISTED
MidWestOne Financial Group
MOFG
| $4.63M | 0.01% |
123,100
+11,800
| +11% | +$393K |
|
1721
C&F Financial
CFFI
$287M
| $4.62M | 0.01% |
92,646
+11,146
| +14% | +$500K |
|
|
CARO
1722
DELISTED
Carolina Financial Corp.
CARO
| $4.61M | 0.01% |
+149,700
| New | +$3.84M |
|
|
SIFI
1723
DELISTED
SI Financial Group, Inc. NEW MD
SIFI
| $4.54M | 0.01% |
294,800
+59,400
| +25% | +$830K |
|
1724
Consolidated Water Co
CWCO
$500M
| $4.53M | 0.01% |
417,487
+37,287
| +10% | +$411K |
|
1725
Clear Channel Outdoor Holdings
CCO
$1.19B
| $4.53M | 0.01% |
896,100
+34,600
| +4% | +$193K |
|
Similar funds
Jim Simons's Q4 2016 Portfolio in Review
As of Q4 2016, Jim Simons held 3,715 positions worth $63.2B, up 12% from $56.6B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
Jim Simons deployed $5.07B of net new capital in Q4 2016, opening 418 new positions and adding to 1,792 existing holdings. Its largest new stake was Broadcom: 10,144,960 shares worth $179M.
By sector, the portfolio is most concentrated in Financials at 15% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $227M trimmed.
- Jim Simons's largest Q4 2016 buy was Broadcom: 10,144,960 shares worth $179M.
- Jim Simons added most to Gilead Sciences in Q4 2016, an estimated $247M increase.
- Jim Simons's biggest Q4 2016 reduction was Bristol-Myers Squibb, cutting an estimated $227M.
- Jim Simons fully exited Alphabet (Google) Class C in Q4 2016, selling an estimated $205M.
- Jim Simons's ten largest holdings make up 7.2% of its $63.2B portfolio in Q4 2016.
- Jim Simons opened 418 new positions and closed 494 in Q4 2016.
- Jim Simons's portfolio value rose 12% quarter-over-quarter to $63.2B.
Based on Renaissance Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.